Co-Diagnostics, Inc. to Present at Utah Mosquito Abatement Association Conference
October 29 2018 - 6:30AM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, proprietary platform for the
development of molecular diagnostic tests, announced today that it
will be offering a presentation of its mosquito vector control
program at the 71st Annual Utah Mosquito Abatement Association
conference in Ogden, Utah on October 29, 2018.
From the website of the Utah Mosquito Abatement Association
(UMAA), the UMAA was founded in 1948, with the goal of promoting
close cooperation among those concerned with, or interested in
mosquito control and related work, to increase the knowledge and
advance the cause of mosquito abatement in an efficient and
effective manner compatible with the goals of a sound
environment.
Vector is the term used to describe an organism that transmits
infectious disease across human or animal populations.
Co-Diagnostics’ vector control program will involve technology
provided by the Company for use in vector control services to test
mosquito populations where the insect is known or suspected to act
as a vector. The UMAA conference will include a brief presentation
of the technology used by the Company in vector control programs,
as well as meetings with several department heads and directors of
organizations across the state involved with control and abatement
of mosquitos carrying diseases like West Nile virus.
Co-Diagnostics CEO Dwight Egan commented, “We believe
Co-Diagnostics is an ideal partner to provide support in pairing
disease detection with vector control programs. Our proprietary
design platform allows us to provide products that meet this demand
via patented, state-of-the-art technology that represents a leap
forward in the understanding of real-time PCR molecular
diagnostics. Tests used in vector control programs are not intended
to diagnose humans, and are therefore subject to different
regulatory requirements. This will allow our products to be
manufactured locally in the Company’s ISO 13485:2016 facility, and
sold throughout the United States without 510(k) clearance or
Premarket Authorization (“PMA”) from the FDA.
“The opportunity to provide vector control tests extends
throughout vast regions of the world that are home to more than 2
billion people who are vulnerable to serious infections from
mosquitoes. Co-Diagnostics has many tests completed or in
development with direct vector control applications, including
those for Zika, tuberculosis, malaria, and Zika/dengue/chikungunya
multiplex, among others.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company with a proprietary diagnostic testing
technology and development platform that intends to manufacture and
sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and license the use of its platform to other non-competing
developers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking
statements in this release include statements regarding the (i) use
of funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181029005252/en/
Company Contact:Co-Diagnostics, Inc.Andrew
BensonCo-Diagnostics Investor
Relations801-438-1036investors@codiagnostics.comorInvestor
Contact:Lytham Partners, LLCJoe Diaz, Robert Blum and Joe
Dorame602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024